Dantron

From Wikipedia, the free encyclopedia

Dantron
Systematic (IUPAC) name
1,8-dihydroxyanthracene-9,10-dione
Identifiers
CAS number 117-10-2
ATC code A06AB03 A06AB53 A06AG03
PubChem 2950
Chemical data
Formula C14H8O4 
Mol. mass 240.211 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral, rectal (enema)
"Dantron" is also a trade name of ondansetron, an unrelated drug, in South Africa.

Dantron (also known as chrysazin) is an anthraquinone derivative, 1,8-dihydroxyanthraquinone, used in some countries as a stimulant laxative. In the USA it is considered to be a carcinogen,[1] and is therefore not used. In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer (i.e. it is mainly used in palliative care to counteract the constipating effects of opioids)

It has the notable side-effect of causing red-coloured urine.

Danthron was the British Approved Name, but it has now been changed to "dantron" in harmony with the recommended International Nonproprietary Name (rINN).

[edit] References

  1. ^ Danthron substance profile at the National Toxicology Program website